PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Kodiak
Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed
to researching, developing and commercializing transformative
therapeutics to treat high prevalence retinal diseases, today
announced the closing of its previously announced underwritten
public offering of 5,972,222 shares of its common stock, which
includes 778,985 shares sold pursuant to the underwriters' exercise
in full of their option to purchase additional shares, at a price
to the public of $108.00 per share.
The aggregate gross proceeds from the offering were approximately
$645.0 million, before deducting the
underwriting discounts and commissions and estimated offering
expenses payable by Kodiak Sciences.
J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI acted as
joint book-running managers for the offering. Truist Securities
acted as lead manager.
The shares described above were offered by Kodiak Sciences
pursuant to an effective shelf registration statement on Form S-3,
including a base prospectus, that was previously filed by Kodiak
Sciences with the Securities and Exchange Commission (the "SEC"). A
final prospectus supplement and accompanying prospectus relating to
the offering have been filed with the SEC and are available on the
SEC's website located at http://www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus relating to
the offering may be obtained from: J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by telephone
at 866-803-9204 or by email at prospectus-eq_fi@jpmchase.com;
Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180
Varick Street, 2nd Floor, New York, New
York 10014 or by email at prospectus@morganstanley.com;
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York,
NY 10022, by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com; or Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor,
New York, NY 10055, by telephone
at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to
researching, developing and commercializing transformative
therapeutics to treat high prevalence retinal diseases. Founded in
2009, we are focused on bringing new science to the design and
manufacture of next generation retinal medicines to prevent and
treat the leading causes of blindness globally. Kodiak's lead
product candidate, KSI-301, is a novel anti-VEGF antibody
biopolymer conjugate being developed for the treatment of retinal
vascular diseases including age-related macular degeneration, a
leading cause of blindness in elderly patients, and diabetic eye
diseases, a leading cause of blindness in working-age patients.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak
logo are registered trademarks or trademarks of Kodiak Sciences
Inc. in various global jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-closing-of-645-0-million-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301178117.html
SOURCE Kodiak Sciences Inc.